Progressive supranuclear palsy. Clinical and pharmacologic update.

Area of Science:

• Neurology
• Neuroscience
• Pathology

Background:

• Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disease.
• It is often misdiagnosed or diagnosis is delayed due to variable presentations.
• Distinguishing PSP from Parkinson's disease is crucial for appropriate management.

Purpose of the Study:

• To outline the distinct clinicopathologic features of PSP.
• To highlight diagnostic challenges and key differentiating signs.
• To describe pathological findings and current treatment limitations.

Main Methods:

• Clinical observation and differentiation from Parkinson's disease.
• Description of characteristic neurological signs (ophthalmoparesis, rigidity, gait).
• Summary of neuropathological findings in PSP brains.

Main Results:

• Supranuclear ophthalmoparesis, particularly downward gaze palsy, is a hallmark of PSP.
• Axial rigidity, pseudobulbar palsy, and parkinsonism without tremor are key clinical indicators.
• Pathology reveals neuronal loss, gliosis, and unique neurofibrillary tangles in specific brain regions.

Conclusions:

• PSP is a distinct clinicopathologic entity requiring careful diagnosis.
• Early recognition of characteristic signs can improve diagnostic accuracy.
• Etiology remains unknown, and treatment options are limited, though early dopamine agonist therapy may offer some benefit.